Clinical Trials Browser

Phase 2 × envafolimab × 90 days × Clear all

NCT06059261 2026-02-18

Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT07327411 2026-01-08

Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors

Phase 2 Not yet recruiting

Other solid neoplasm

Advanced Refractory Solid Tumors